Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$471.05 USD

471.05
535,639

+0.97 (0.21%)

Updated Aug 11, 2025 12:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

TransEnterix (TRXC) Soars: Stock Adds 14.2% in Session

by Zacks Equity Research

TransEnterix (TRXC) saw a big move last session, as its shares jumped more than 14% on the day, amid huge volumes.

    Zacks Equity Research

    Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut

    by Zacks Equity Research

    Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.

      John Blank headshot

      Trade Tensions Begin to Escalate: Global Week Ahead

      by John Blank

      Markets will be gradually informed by developments in U.S.-China trade tensions over the coming weeks.

        Zacks Equity Research

        Chemed (CHE) Stock is Worth a Bet Right Now: Here's Why

        by Zacks Equity Research

        Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.

          Zacks Equity Research

          Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

          by Zacks Equity Research

          Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

            Zacks Equity Research

            BioScrip (BIOS) Q1 Loss Wider Than Expected, Revenues Beat

            by Zacks Equity Research

            BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.

              Ryan McQueeney headshot

              Anatomy of Success: Intuitive Surgical (ISRG)

              by Ryan McQueeney

              If investors had followed our model when it identified this futuristic healthcare technology manufacturer, they would have achieved massive profits.

                Zacks Equity Research

                Here's Why You Should Invest in Intuitive Surgical Right Now

                by Zacks Equity Research

                Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.

                  Zacks Equity Research

                  STERIS (STE) Q4 Earnings & Revenues Beat Estimates, Up Y/Y

                  by Zacks Equity Research

                  Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.

                    Zacks Equity Research

                    Wright Medical (WMGI) Beats on Q1 Earnings, Keeps Guidance

                    by Zacks Equity Research

                    Wright Medical's (WMGI) Q1 results solid; growth in upper and lower extremities segments encourages.

                      Zacks Equity Research

                      Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates

                      by Zacks Equity Research

                      Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.

                        Zacks Equity Research

                        Penumbra (PEN) Q1 Earnings & Revenues Top Estimates, View Up

                        by Zacks Equity Research

                        Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.

                          Zacks Equity Research

                          Luminex (LMNX) Beats Q1 Estimates on ARIES Platform Strength

                          by Zacks Equity Research

                          Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.

                            Zacks Equity Research

                            Fresenius Medical (FMS) Misses on Q1 Earnings, Lowers View

                            by Zacks Equity Research

                            Lackluster performance in North America and foreign exchange headwinds mar Fresenius Medical's (FMS) bottom line in Q1.

                              Zacks Equity Research

                              Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3

                              by Zacks Equity Research

                              Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.

                                Zacks Equity Research

                                Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact

                                by Zacks Equity Research

                                We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.

                                  Zacks Equity Research

                                  Amedisys (AMED) Q1 Earnings, Revenues Beat on Overall Growth

                                  by Zacks Equity Research

                                  Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.

                                    Zacks Equity Research

                                    Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y

                                    by Zacks Equity Research

                                    Phibro (PAHC) witnesses year-over-year improvement across all segments in Q3.

                                      Zacks Equity Research

                                      DaVita (DVA) Beats Q1 Earnings Estimates, Reiterates View

                                      by Zacks Equity Research

                                      Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q1.

                                        Zacks Equity Research

                                        PetMed (PETS) Q4 Earnings Top Estimates, Reorder Sales Solid

                                        by Zacks Equity Research

                                        PetMed (PETS) Q4 sales rise on increased reorders

                                          Zacks Equity Research

                                          Align Technology (ALGN) Beats on Earnings and Revenues in Q1

                                          by Zacks Equity Research

                                          Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q1.

                                            Zacks Equity Research

                                            Bruker (BRKR) Q1 Earnings & Revenues Beat, Margins Expand

                                            by Zacks Equity Research

                                            Bruker's (BRKR) Q1 benefits from improved European revenues, rising year over year in high-single digits.

                                              Zacks Equity Research

                                              ABIOMED (ABMD) Earnings Beat Estimates in Q4, View Impressive

                                              by Zacks Equity Research

                                              ABIOMED (ABMD) gains on surging Impella revenues, number of regulatory approvals.

                                                Zacks Equity Research

                                                Surmodics (SRDX) Beats on Q2 Earnings & Revenues, Raises View

                                                by Zacks Equity Research

                                                Surmodics' (SRDX) second-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                                  Zacks Equity Research

                                                  DENTSPLY (XRAY) Beats Q1 Earnings Estimates, Lowers View

                                                  by Zacks Equity Research

                                                  Strong performance in Europe and Rest of World boosts DENTAPLY's (XRAY) performance in Q1. However, a lowered guidance indicates looming concerns.